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Abstract
The ﬁloviruses, Marburg and Ebola, have the dubious distinction of being associated with some of the highest case-fatality rates of any known
infectious disease—approaching 90% in many outbreaks. In recent years, laboratory research on the ﬁloviruses has produced treatments and
vaccines that are effective in laboratory animals and that could potentially drastically reduce case-fatality rates and curtail outbreaks in humans.
However, there are signiﬁcant challenges in clinical testing of these products and eventual delivery to populations in need. Most cases of ﬁlovirus
infection are recognized only in the setting of large outbreaks, often in the most remote and resource-poor areas of sub-Saharan Africa, with little
infrastructure and few personnel experienced in clinical research. Signiﬁcant political, legal, and socio-cultural barriers also exist. Here, we review
the present research priorities and environment for ﬁeld study of the ﬁlovirus hemorrhagic fevers and outline a strategy for future prospective
clinical research on treatment and vaccine prevention.
© 2008 Elsevier B.V. All rights reserved.
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1. Introduction
The ﬁloviruses are nonsegmented, single-stranded negative-
sense RNA viruses with an unusual ﬁlamentous morphology.
The family Filoviridae is divided into two genera, Ebolavirus
and Marburgvirus. Four species of ebolavirus (Zaire, Sudan,
Ivory Coast and Reston) and one of marburgvirus (Lake Victo-
riamarburgvirus)arerecognized(Table1).Filovirusescirculate
in sub-Saharan Africa where they occasionally cause large out-
breaksofseverehemorrhagicfever(Fig.1)(Bausch,2007a).The
natural reservoir of the ﬁloviruses remains unknown, although
bats are suspected (Leroy et al., 2005; Swanepoel et al., 2007;
Towneretal.,2007).Transmissionbetweenhumansresultsfrom
direct contact with infected blood and bodily ﬂuids (Dowell et
al., 1999; Bausch et al., 2007b). No speciﬁc antiviral therapies
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or vaccine are yet available. The primary control strategy relies
on thorough case identiﬁcation and contact tracing, with imme-
diate isolation of suspected cases in specialized isolation wards
(CDC/WHO, 1998; Bausch, 2007b).
Increasing frequency of natural transmission of the
ﬁloviruses in sub-Saharan Africa, as well as concerns about
bioterrorism and imported cases, have heightened their impor-
tancetopublichealthoverthepastfewdecades.Theseconcerns
havefosteredintenselaboratory-basedresearcheffortsinindus-
trialized countries on the pathogenesis, treatment, and vaccine
prevention for ﬁlovirus hemorrhagic fever (FHF) that hold the
potential to reduce case-fatality rates and drastically curtail out-
breaks (Schuler, 2005). Several candidate therapies have shown
efﬁcacy in nonhuman primates if initiated soon after virus chal-
lenge,andanumberofvaccineshavebeendevelopedthatprotect
these animals against otherwise uniformly lethal infection.
The research advances on treatments and vaccines for FHF
may soon render products ready for clinical testing. However,
while the basic science stages of research takes place largely
in the controlled environment of high-containment laboratories,
if clinical research on FHF is to be carried out it must occur in
0166-3542/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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Table 1
Laboratory-conﬁrmed cases and outbreaks of ﬁloviral hemorrhagic fever
Virus and date of onset of transmission Epicenter(s) Source of primary infection Factors contributing to spread #Cases CFR (%)
Marburgvirus
1967 Marburg and Frankfurt,
Germany; Belgrade,
Yugoslavia (present Serbia)
Imported monkeys from
Uganda
Dissection of monkeys to
harvest organs, nosocomial
transmission
32 22
1975 Rhodesia (present
Zimbabwe)/South Africaa
Unknown Nosocomial transmission 3 33
1980 Kisumu and Nairobi, Kenya Exposure in cave? Monkey
contact?
Nosocomial transmission 2 50
1987 Mombasa, Kenya Exposure in cave? – 1 100
1998 Durba, DRC Exposure in gold mine Repeated primary
introductions into humans
154 83
2004 U´ ıge, Angola Unknown Nosocomial and
community-based
transmission
252 90
2007 Kamwenge, Uganda Exposure in gold mine? Presumed primary
introductions in 2 cases, with
subsequent person–person
spread
42 5
Zaire ebolavirus
1976 Yambuku, Zaire (present
DRC)
Unknown Nosocomial transmission 318 88
1977 Tandala, Zaire Unknown – 1 100
1994 Ogoou´ e-Ivindo Province,
Gabon
Unknown Traditional healing practices,
nosocomial and
community-based
transmission
49 59
1995 Kikwit, DRC Unknown Nosocomial transmission 315 81
1996 Ogoou´ e-Ivindo Province,
Gabon
Consumption of dead chimp Secondary spread to
caregivers
31 68
1996 Ogoou´ e-Ivindo Province,
Gabon
Unknown Exposure while hunting,
traditional healing practices
60 75
1996 Johannesburg, South Africa Imported from Gabon by
infected doctor
Nosocomial transmission 2 50
2001 Ogoou´ e-Ivindo Province,
Gabon and Cuvette Ouest
Region, ROC
Hunting and consumption of
nonhuman primates
Exposure while hunting,
secondary spread to
caregivers, traditional healing
practices
124 78
2002 Cuvette Ouest Region, ROC Hunting and consumption of
nonhuman primates
Exposure while hunting,
secondary spread to
caregivers
143 89
2003 Cuvette Ouest Region, ROC Hunting and consumption of
nonhuman primates
Exposure while hunting,
secondary spread to
caregivers
35 83
2007 Kasai Occidental Province,
DRC
Unknown Unknown 264b 71
Sudan ebolavirus
1976 Maridi and Nzara, Sudan Unknown Nosocomial transmission 284 53
1979 Nzara, Sudan Unknown Nosocomial transmission 34 65
2000 Gulu, Uganda Unknown Nosocomial and community
transmission
425 53
2004 Yambio, Sudan Unknown Unknown 17 41
Ivory Coast ebolavirus
1994 Ta¨ ı Forest, Cˆ ote d’Ivoire Necropsy of chimpanzee – 1 0
Ebolavirus, species undeterminedc
2007c Bundibugyo District, Uganda Unknown Unknown 149c 25
Laboratory-acquired infections and infections due to Reston ebolavirus, which has not been epidemiologically linked to Africa or associated with human disease,
are excluded. Abbreviations: CFR: case-fatality rate, DRC: Democratic Republic of the Congo, ROC: Republic of the Congo.
a The outbreak was initiated in travelers who passed through Zimbabwe on their way to South Africa. The place where infection occurred is unknown.
b Although a total of 264 cases and 187 deaths were reported by the DRC Ministry of Health, simultaneous outbreaks of malaria, typhoid, and shigellosis make it
difﬁcult to ascertain the percentage of these actually attributable to Ebola hemorrhagic fever. Only 26 cases were laboratory conﬁrmed.
c This outbreak is still ongoing at the time of writing of this article. Initial reports attribute it to a new species of ebolavirus, but details are not yet available. Case
numbers and the case-fatality rate are up until January 4, 2008.Author's personal copy
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Fig. 1. The known distribution of human cases of ﬁloviral hemorrhagic fever
(FHF). Countries where human cases of Marburg or Ebola hemorrhagic fever
have been conﬁrmed are noted in gray. Areas where more than one outbreak
have been noted are indicated by cross-hatching, and include the border area
of Gabon and the Republic of the Congo, central Democratic Republic of the
Congo (DRC), and northern Uganda/southern Sudan/northeastern DRC.
endemicareasinsub-SaharanAfrica,mostlikelyunderoutbreak
conditions in areas with rudimentary medical infrastructures. In
fact, any plan to conduct prospective clinical research on FHF
must deal with a staggering array of scientiﬁc, logistical, polit-
ical, social, ﬁnancial, legal, and ethical challenges. Here, we
review the progress made to date in understanding the patho-
genesis,clinicalpresentation,treatment,andvaccineprevention
of FHF, then describe the settings in sub-Saharan Africa where
ﬁeldresearchonFHFmusttakeplace,andﬁnallyoutlineastrat-
egy for prospective clinical research on treatment and vaccine
prevention in this challenging environment.
2. Research progress
AdecadeofworkbyteamsattheCentersforDiseaseControl
andPrevention(CDC),theUSArmyMedicalResearchInstitute
forInfectiousDiseases,thePublicHealthAgencyofCanadaand
otherlaboratorieshasledtomajorprogressinunderstandingthe
pathogenesisoftheFHFsanddevelopingexperimentaltherapies
and vaccines. Studies have been based on models of infection
in mice, guinea pigs, and nonhuman primates, supplemented by
a limited amount of clinical data obtained from humans during
outbreaks in Africa.
2.1. Pathogenesis
The major clinical features of FHF appear to result from an
intensesystemicinﬂammatoryresponseresemblingsepticshock
(Bray and Mahanty, 2003; Mahanty and Bray, 2004). Stud-
ies in nonhuman primate models have shown that monocytes,
macrophages and dendritic cells, the ubiquitous “sentinels” that
normally guard the body against microbial invasion, are the
major sites of initial viral replication and play the central role
in pathogenesis (Schnittler et al., 1993; Zaki and Goldsmith,
1999; Bosio et al., 2003, 2004; Geisbert et al., 2003b; Bray
and Geisbert, 2005). Virus is then distributed by circulating
monocytes/macrophages to a wide variety of organs and cell
types. The system-wide release of proinﬂammatory cytokines
and chemokines by these infected cells causes fever, vascular
instability, hypotension and shock, and ultimately multi-organ
system failure (Mahanty and Bray, 2004; Hoenen et al., 2006).
The synthesis of cell surface tissue factor triggers the extrin-
sic coagulation pathway (Hensley et al., 2002; Geisbert et al.,
2003c;HensleyandGeisbert,2005).Innonhumanprimatemod-
els of EHF, disseminated intravascular coagulation is noted by
theseconddaypost-infection,asevidencedbytheappearanceof
d-dimersintheplasma(Geisbertetal.,2003c).Extensivenecro-
sis is noted, especially in the liver, although it is usually not to
a degree to account for death (Egbring et al., 1971; Martini,
1971; Stille and Bohle, 1971; Gear et al., 1975; Geisbert and
Jaax, 1998; Zaki and Goldsmith, 1999). Although endothelial
cell infection is consistently noted on post-mortem tissues col-
lectedfromﬁlovirusvictims(ZakiandGoldsmith,1999),studies
in nonhuman primates suggest that this does not occur until late
in the course of the disease (Geisbert et al., 2003d).
The suppression of host-immune responses is a key com-
ponent of ﬁlovirus pathogenesis, especially for Ebola virus
infection, where two virus proteins have been shown to sup-
pressinterferonresponses(Basleretal.,2003;Reidetal.,2006).
Furthermore, in most fatal cases, patients fail to produce anti-
bodies against the ﬁlovirus and die with persistent high viremia
(Ksiazek et al., 1999; Sanchez et al., 2004). Because the initia-
tionofanadaptiveimmuneresponserequiresthatdendriticcells
present viral antigens to lymphocytes, the explanation is readily
available; dendritic cells are a major site of ﬁloviral replication,
which blocks their maturation and causes their death through
necrosis(Geisbertetal.,2003b;Mahantyetal.,2003).Although
lymphocytesremainfreeofinfection,theyaredestroyedinmas-
sive numbers over the course of illness through apoptosis, again
similar to the process seen in septic shock (Baize et al., 2000;
Geisbert et al., 2000; Hotchkiss and Karl, 2003). Thus, anti-
apoptotic therapies that can preserve immune function might
prove to be future therapies for FHFs (Parrino et al., 2007).
2.2. Clinical presentation
Although increasingly organized surveillance and response
systems for ﬁlovirus outbreaks in the last decade have allowed
for more frequent clinical observation, there is still a dearth
of detailed and systematically collected clinical data. With the
exception of Reston ebolavirus, which does not appear to be
pathogenictohumans,alltheﬁlovirusesappeartoproduceasim-
ilar illness. The presenting symptoms are difﬁcult to distinguish
from a host of other febrile illnesses. After an incubation period
of around 8 days (range 3–21 days), disease typically begins
with the abrupt onset of fever, chills, headache, general malaise,
anorexia, sore throat, and chest, back, muscle, and joint pains
(Martini et al., 1968; Egbring et al., 1971; Martini, 1971; StilleAuthor's personal copy
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and Bohle, 1971; Todorovitch et al., 1971; Gear et al., 1975;
Pattyn et al., 1977; Anon., 1978; Smith et al., 1982; Nikiforov
et al., 1994; Johnson et al., 1996; Bwaka et al., 1999; Bausch
et al., 2006; Colebunders et al., 2007). Conjunctival injection
or hemorrhage is seen in up to half of patients at presentation,
but is not typically accompanied by itching, discharge, or rhini-
tis. Patients themselves rarely refer to problems with their eyes,
other than the cosmetic complaint of redness. A ﬂeeting mac-
ulopapular or morbilliform rash is sometimes noted over the
thorax, face and arms, especially in Caucasians. A dry cough,
sometimes accompanied by a few scattered rales on ausculta-
tion, is frequently noted, but prominent pulmonary symptoms
or the presence of productive sputum early in the course of dis-
ease are uncommon. Jaundice is not typical and should suggest
a different diagnosis.
Gastrointestinal signs and symptoms develop within the ﬁrst
few days of illness, including nausea and vomiting, epigas-
tric and abdominal pain and tenderness (especially in the right
upper quadrant in Ebola hemorrhagic fever (EHF)), and diar-
rhea. FHF has sometimes been mistaken for acute appendicitis
or other abdominal emergencies. Hepatosplenomegaly is fre-
quently seen, but it is unknown whether this is speciﬁc to FHF
or simply represents the high underlying prevalence of hep-
atosplenomegaly in populations in sub-Saharan Africa where
most clinical observations have been made.
In severe cases, vascular instability develops, usually 4–5
daysaftertheonsetofsymptoms,andmaybeevidencedbyfacial
ﬂushing, edema, proteinuria, bleeding, hypotension, and shock.
Hemorrhage is most often gastrointestinal in nature (vomiting
blood or blood passed from the rectum), but vaginal bleed-
ing, petechiae, purpura, nose bleeds, and bleeding from the
gums and venupuncture sites may be seen. Coughing up blood
(hemoptysis) and hematuria are less frequent. Hemorrhage is
almost never present in the ﬁrst 2 days of illness. Central
nervous system manifestations, including disorientation, gait
anomalies, convulsions, and hiccups may be noted in end-stage
disease.
Common clinical laboratory ﬁndings include WBC abnor-
malities (moderate leucopenia and lymphopenia with atypical
lymphocytes early in the course of disease, with late leuko-
cytosis and left shift), hemoconcentration, mild-to-moderate
thrombocytopenia, blood coagulation abnormalities consistent
withdisseminatedintravascularcoagulopathy,andelevatedhep-
atic transaminases (typically AST>ALT), amylase, blood urea
nitrogen, and creatinine (Egbring et al., 1971; Martini, 1971;
Stille and Bohle, 1971; Gear et al., 1975; Rollin et al., 2007).
Radiographic examination has not been reported.
TheclinicalcourseofFHFusuallyunfoldsquiterapidly,with
death in fatal cases 7–10 days after symptom onset. Ebola Zaire
and Marburg virus infection in sub-Saharan Africa are consis-
tently associated with case fatalities of 80–90%, and Sudan
ebolavirus 50–60% (Peters and Zaki, 2006). Mild and even
asymptomatic cases have been reported (Leroy et al., 2001;
Borchert et al., 2002). Common indicators of a poor progno-
sis include shock, bleeding, neurological manifestations, high
viremia,andelevatedlevelsofAST(Sanchezetal.,2004;Rollin
et al., 2007). High maternal and fetal mortality are also noted
in pregnant patients with FHF, in whom vaginal bleeding and
spontaneous abortion usually occurs (Mupapa et al., 1999b).
2.3. Drug therapy
No licensed antiviral drug is efﬁcacious against the
ﬁloviruses.Convalescentserumandwholebloodhavebeenused
inafewinstances,buttheirefﬁcacyhasneverbeenconvincingly
demonstrated(Emondetal.,1977;Mupapaetal.,1999a).Labo-
ratorystudiesofpoly-andmonoclonalantibodieshavemetwith
mixed results, although results from perhaps the most relevant
animalmodel,cynomolgusmonkeys,havenotbeenencouraging
(Jahrling et al., 1996, 1999, 2007; Wilson et al., 2000; Gupta et
al.,2001;Takadaetal.,2006;Oswaldetal.,2007).Interferon-,
recombinantinterferon,andextracorporealbloodtreatmentwith
hemosorbents and dialysis have been tried in a few patients who
survived, but it is not clear that these measures were responsible
for the favorable outcome (Emond et al., 1977; Nikiforov et al.,
1994; Kudoyarova-Zubavichene et al., 1999). The nucleoside
analogribavirin,whichhasprovenbeneﬁcialinsomeotherviral
hemorrhagic fevers (VHFs), has no effect against the ﬁloviruses
(Huggins, 1989).
Experimental therapies for the FHFs can be divided into
those designed to directly block ﬁlovirus replication and those
that act indirectly through the modiﬁcation of deleterious host
responses. In the ﬁrst category are antisense oligonucleotides
andshortinterferingRNA(siRNA)moleculesthathavebecome
a focus of intense interest as therapies for a wide range of dis-
eases (Spurgers et al., 2008; Warﬁeld et al., 2006a). Antisense
phosphorodiamidate morpholino oligomers (PMOs) targeting
predicted sequences in the mRNA of 3 viral genes protected
75%ofrhesusmacaquesagainstZaireviruswhentreatmentwas
begun before viral challenge (Enterlein et al., 2006; Warﬁeld
et al., 2006b). Treatment with siRNA has been successful in
guinea pigs, but results have not yet been reported for nonhu-
man primates (Geisbert et al., 2006). Both PMOs and siRNA
have so far proven safe in animal and human testing. Improved
delivery systems and combinations of molecules targeting mul-
tiple viral genes may further improve the efﬁcacy of these
approaches. Certain other small molecules and licensed prepa-
rations of type I interferon are active in vitro and in rodent
models,butnotinnonhumanprimates(BrayandParagas,2002).
S-adenosylhomocysteine hydrolase inhibitors have also shown
some success in the mouse model (Bray et al., 2000).
Treatments aimed at modifying deleterious host responses
have derived from improved understanding of the pathogene-
sis of septic shock and its similarity to FHF. Recognizing that
disseminated intravascular coagulation is triggered by the bind-
ing of tissue factor on the surface of infected macrophages
to circulating factor VII, Geisbert et al. (2003a) attempted to
block this interaction by giving daily injections of recombinant
nematode anticoagulant protein C2 (rNAPC2), a product that
is in advanced human trials for a number of applications. A
33% reduction in mortality was noted when 9 macaques were
treated within 1 day after Ebola Zaire virus challenge. Most ani-
mals showed a marked reduction in coagulopathy and a striking
decrease in levels of proinﬂammatory mediators. A 100-foldAuthor's personal copy
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drop in peak viremia was noted in the 3 surviving animals. The
same therapy produced a lesser degree of beneﬁt in macaques
infected with the highly virulent Angola strain of marburgvirus
(Geisbert et al., 2007).
Both septic shock and FHF are characterized by a signiﬁ-
cant fall in the plasma protein C level over the course of illness.
Intravenous infusion of activated protein C has shown beneﬁt
for the treatment of gram-negative sepsis in large clinical tri-
als (Fourrier, 2004). Administration of activated protein C to a
group of 11 Zaire virus-infected monkeys resulted in a signiﬁ-
cant prolongation of the mean time to death and survival of 2 of
the animals (Hensley et al., 2007).
Despite some promising results, it must be recognized that
successfulinterventionshavebeeninitiatedeitherbeforeorsoon
after virus challenge. No therapy, licensed or experimental, has
yet been shown to protect nonhuman primates against an oth-
erwise lethal ﬁlovirus infection once disease has begun. The
critical stages of disease progression and points at which inter-
vention may be successful remain largely unknown.
2.4. Vaccines
A number of new vaccine candidates have been shown to
protect nonhuman primates against otherwise uniformly lethal
challengewiththeﬁloviruses.Theﬁrstsuccessfulapproachused
a prime-boost strategy in which a series of 3 injections of DNA
encoding the nucleoprotein and surface glycoprotein of Zaire
virus was followed by a single inoculation of a replication-
defective recombinant adenovirus encoding the same antigens
(Sullivan et al., 2000). Subsequent testing showed that the
adenovirus-vectored vaccine was protective when given alone
as little as 4 weeks before challenge (Sullivan et al., 2003). The
DNAcomponenthasbeenshowntobesafeandimmunogenicin
humansandtheadenovirusproductisalsocurrentlyundergoing
Phase I testing (Martin et al., 2006). Both the full prime-boost
series and fast-acting adenovirus vaccine could play important
roles in dealing with EHF; the former could be used to generate
long-lasting immunity in laboratory workers and members of
international outbreak response teams and the latter to protect
local health workers at outbreak sites.
Anotherpromisingadvancehasbeenthedevelopmentoflive,
recombinantvesicularstomatitisvirus(rVSV)vaccinesexpress-
ing the surface glycoprotein of ebolavirus or marburgvirus
(Jonesetal.,2005).Asingleinjectionofeitherproductprotected
nonhumanprimatesagainstsubsequentchallengewiththecorre-
spondingpathogen,butnocross-protectionwasobserved.These
vaccines were also effective when given by the nasal or oral
route,potentiallyfacilitatingtheiruseinepidemics(Jonesetal.,
2006). Furthermore, the rVSV-Marburg vaccine prevented ill-
nessevenwhengiven30minafterinoculationofalethaldoseof
marburgvirus, suggesting that it may be useful as post-exposure
prophylaxis (Daddario-DiCaprio et al., 2006). The rVSV-Ebola
vaccine was also beneﬁcial when given 30min post-exposure,
preventing the death of 50% of the animals (Feldmann et al.,
2007). Such fast-acting vaccines could potentially be used as
post-exposure prophylaxis after laboratory accidents or in the
ﬁeld when a clear exposure occurs. Although there are con-
cerns over the safety of replication-competent rVSV-vectored
vaccines in sub-Saharan Africa, where considerable numbers of
immunocompromised persons with HIV/AIDS or malnutrition
would likely be vaccinated, preliminary studies in immuno-
compromised nonhuman primates have not indicated problems
(Thomas Geisbert, unpublished data).
A few other vaccine strategies for the FHFs are being
explored; a live recombinant parainﬂuenza virus type 3 vaccine
expressingtheEbolaZairevirussurfaceglycoproteinwasshown
to be protective when given by the intranasal route (Bukreyev et
al., 2007). A preparation of noninfectious ebolavirus-like parti-
cles also protected laboratory primates, though a series of doses
was required (Warﬁeld et al., 2007).
3. Filovirus outbreaks—controlled chaos
Except for outbreaks related to the inadvertent importation
of infected monkeys to Europe, cases of FHF in humans have
been exclusively noted in sub-Saharan Africa (Table 1 and
Fig. 1). Although seroprevalence data suggest that some degree
ofendemictransmissionprobablyexistsbeneaththethresholdof
detection, especially for ebolaviruses (Monath, 1999; Bausch et
al., 2003), ﬁlovirus transmission is generally recognized only in
outbreakform(Bausch,2007a).Thelargestoutbreaks(300–400
cases) are invariably a result of nosocomial ampliﬁcation. Thus,
itisnosurprisethattheyaretypicallyseeninthemostremoteand
resource-poor areas of sub-Saharan Africa where the healthcare
delivery system and infection control standards have deterio-
rated. In most cases, the roots of this deterioration can be traced
to years of civil unrest and violence. The patient-care setting
often consists of multi-bed units, frequently without running
water, a limited array of basic antimalarials, antibiotics, and
analgesics, and an at-best rudimentary diagnostics and clini-
cal laboratory. In practical terms, this translates to a dearth
of personnel and supplies, with a typical scenario being an
understaffed health center with undertrained workers without
ready access to gloves and other personal protective equipment,
sometimes tempted by the difﬁcult circumstances to reuse con-
taminated needles and syringes. The physical infrastructure is
oftenequallyinadequate,withnostableelectricity,refrigerators
or freezers. Telecommunications and Internet access may be
difﬁcult or even non-existent, and transport to the distant major
population centers limited and arduous.
Outbreaks begin when a human is infected through con-
tact with the still unidentiﬁed primary reservoir (perhaps a bat)
(Leroyetal.,2005;Swanepoeletal.,2007;Towneretal.,2007),
or an infected nonhuman primate, with ampliﬁcation resulting
from secondary transmission between humans, which typically
takes place when family members or healthcare workers are
exposed to the patient’s blood and bodily ﬂuids. As the number
of cases begins to mount, the community is confronted with a
mysterious and fearful new scourge (Bausch, 2001). Traditional
belief systems common in Central Africa often result in the dis-
ease being attributed to sorcery or poisoning rather than to a
virus(HewlettandAmola,2003;Hewlettetal.,2005).Deathsof
healthcareworkersoftenoccur(andareoftenadecisivecluethat
aﬁlovirusiscirculating),sometimespromptingotherworkerstoAuthor's personal copy
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ﬂee their posts, further destabilizing the already-fragile health-
care delivery system (Bausch, 2001). Laboratory conﬁrmation,
which requires sending specimens to one of the few labora-
tories in the world with the necessary reagents and biosafety
measures to perform ﬁlovirus diagnostics, usually lags. Conse-
quently, a concerted international outbreak response is typically
not mounted until months after the occurrence of the ﬁrst case,
which is almost always identiﬁed retrospectively (Bausch and
Rollin, 2004; Bausch, 2007a). Finally, an outbreak control team
composed largely of foreigners and government representatives
fromadistantcapitaldescendsuponthevillage.Aﬂurryofactiv-
ity ensues, with creation of committees and control programs. If
clinical research on the ﬁloviruses is to take place, it must occur
inthistenseandchaoticenvironmentandbeexecutedsimultane-
ously and without compromising the multifaceted components
of outbreak control.
Standard control measures for the ﬁloviruses call for hospi-
talization of patients in an isolation ward (CDC/WHO, 1998;
Bausch, 2006)( Fig. 2). This is the setting where future clinical
researchwouldlogicallytakeplace.Ironically,inadditiontothe
Fig. 2. Isolation wards for patients with ﬁloviral hemorrhagic fever (FHF). Clinical research on FHF in sub-Saharan Africa would most likely take place in isolation
wardsestablishedduringthecourseofoutbreaks.Theinfrastructureandequipmentavailableatthesesitesmayvarydrastically.Althoughvirtuallyallare“make-shift”
in response to an outbreak, some wards are set up in pre-existing hospitals and may beneﬁt from other services available at the site, while others are situated in local
health clinics or rapidly constructed de novo in remote areas and offer little in the way of modern medical care. Some examples are shown. Top row: exterior and
interior of the EHF isolation ward, Kampungu, Democratic Republic of the Congo (DRC), 2007 (Courtesy of M´ edecins Sans Fronti` eres, Belgium). Middle row:
EHF isolation ward, Gulu Regional Hospital, Gulu, Uganda, 2000. Left: workers remove the body of a victim from the isolation ward. Right: interior of the ward
(Photos by Daniel G. Bausch). Bottom row: Marburg hemorrhagic fever, Durba, DRC, 1998. Left: children cluster outside an isolation unit in the local health center.
Right: workers in protective garb prepare to enter the ward (Photos by Daniel G. Bausch).Author's personal copy
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challengespresentedbytheaforementionedlimitationsinphys-
ical infrastructure and personnel, recruitment of patients, even
in large outbreaks, could be a problem (Bausch et al., 2007a).
The inherent severity of ﬁlovirus infection, absence of speciﬁc
antiﬁlovirus therapies, limited availability of supportive mea-
sures, and, at times, the channeling of energies and resources
into community control rather than patient-care have all con-
tributed to the extremely high case-fatality rate. An unfortunate
result of this situation is that the isolation ward is frequently
considered as a place where one goes to die, not survive. Fur-
thermore, the environment of the isolation ward is unfamiliar
and even threatening, with treatment often being administered
by mask-, gown-, and glove-clad foreigners and contact with
family members extremely limited. Death brings the possibility
of being buried in an unfamiliar setting without the traditional
rites so important in African culture, while those who survive to
return to their communities are often ostracized (Boumandouki
et al., 2005). Adding on the vestiges of colonial era suspicion of
foreigners and present-day frictions between ethnic groups, it is
notsurprisingthatresistancetoadmissiontotheisolationwardis
high, and sometimes even violent (Larkin, 2002). In the worst-
case scenario, and if not conducted openly and with cultural
sensitivity, clinical research in this charged setting could run the
risk of meeting with the perception that foreigners and others in
power are experimenting on vulnerable populations. However,
measuresnowroutinelyimplementedintheoutbreakresponseto
ﬁloviruses, including the inclusion of social mobilization teams
and concerted efforts to provide thorough explanation of the
goals and movements of the outbreak response efforts to the
local population, are the right steps to alleviating this concern
(Formenty et al., 2003).
4. A strategy for bringing research products to ﬁeld
testing
The recent success in developing therapies and vaccines that
protect laboratory primates against the ﬁloviruses suggests that
similar approaches may be effective in humans. However, the
typical setting of a ﬁlovirus outbreak in Central Africa, the only
place where human efﬁcacy trials might be possible, presents
an extreme contrast to the highly controlled, resource-rich
environment of high-containment laboratories in industrialized
countries.Althoughhumanefﬁcacytrialsmightbeavoidedalto-
getherthroughuseoftheFoodandDrugAdministration’s(FDA)
so called “animal rule” (Roberts et al., 2008), which allows for
licensure of new drugs and biological products based on evi-
denceofeffectivenessderivedfromstudiesinwell-characterized
animal models when human efﬁcacy studies are not ethical or
feasible,itislikelythatsomeevidenceofefﬁcacyinhumanswill
still be needed before widespread use of any developed product.
As discussed above, communities in Africa most affected by
ﬁloviruses and where treatments and vaccines are most needed,
often harbor signiﬁcant suspicion of outbreak response teams,
including researchers. Distinctly American concepts such as
FDA licensure and the animal rule are unlikely to mean much
to these populations. Some degree of demonstrated efﬁcacy in
humans will likely be required to alleviate their suspicions. Fur-
thermore, even in the United States, licensure based on the
animal rule alone may not bring a sufﬁcient degree of comfort
to allow widespread use, even of a marketed product. Conse-
quently, a strategy to translate discoveries from the laboratory
to the ﬁeld must be considered and take into account the chal-
lenges of conducting high quality and ethically sound research
in some of the world’s poorest nations.
4.1. Prerequisites
Despitethesenseofurgencytointervenewhenfacedwiththe
devastating social and economic impacts of ﬁlovirus outbreaks
in Africa, no compromises can be made on safety. Therapies
and vaccines that show promise in animal models must ﬁrst
progress to Phases I and II clinical trials, which might include
workers in high-containment laboratories and members of out-
breakresponseteams.However,giventheoverwhelminghuman
suffering associated with ﬁlovirus outbreaks, we must explore
ways of safely expediting promising therapies and preventive
strategies to compassionate use.
4.2. Identifying the countries and regions where ﬁlovirus
clinical research could occur
Precisely when and where the next ﬁlovirus outbreak will
occur cannot be predicted. However, past experience and our
growing understanding of the ecology of ﬁloviruses and their
possible reservoirs can help us make some educated guesses
(Peterson et al., 2004a,b; Leroy et al., 2005; Bausch et al., 2006;
Pourrutetal.,2007;Swanepoeletal.,2007;Towneretal.,2007).
Only Ebola Zaire and Sudan virus and Marburg virus, all found
in Central Africa, have been associated with large outbreaks.
Since the ﬁrst discovery of a ﬁlovirus in 1967, the vast majority
ofcaseshavebeenobservedinﬁvecountries:Gabon,theRepub-
licoftheCongo,theDemocraticRepublicoftheCongo,Uganda,
andSudan(Table1andFig.1).AlthoughnumerouscasesofEHF
have also been seen in southern Sudan, that country is excluded
from further consideration here due to the ongoing civil unrest
which would presently constitute an insurmountable barrier to
international research. Furthermore, relative “hot spots” can be
identiﬁed within most of these countries where repeated trans-
missionhasoccurred(Fig.1).Majorhospitalswithintheseareas
could be targeted for development as clinical research centers
for FHF.
4.3. Assembling the partners and devising a plan
To date, ﬁeld research during outbreaks of FHF has been
almost entirely ad hoc, shaped by scientists once they hit
the ground and based on available clinical samples. While
this approach has led to considerable accumulation of knowl-
edge on ﬁlovirus transmission and control, logistic, ethical, and
legalconsiderationsprecludeitsapplicationtoclinicalresearch.
Rather,asuccessfulclinicalresearchplanfortheﬁloviruseswill
requireconsiderableadvancedplanning.Oneapproachwouldbe
to convene a ﬁlovirus clinical research working group, coordi-
nated by the World Health Organization (WHO) and consistingAuthor's personal copy
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ofkeyministryofhealthrepresentatives,clinicians,researchers,
lawyers,andsupportpersonnelfromthetargetregionsinAfrica,
in addition to other international experts on ﬁlovirus research
and clinical management, specialists in research ethics, logisti-
cal and legal support personnel from WHO, and representatives
from any pharmaceutical companies potentially involved.
The working group would determine what clinical research
questions regarding the ﬁloviruses are most urgent and logisti-
cally amenable and devise detailed research protocols for each,
taking into account the sometimes marked differences in social
and ofﬁcial attitudes towards health and governmental pro-
grams between African regions. Because of the great distances
involved, the approach may require developing mobile research
teams and units. An essential element should be that all inter-
ventionsbeconductedinamannerthatpermitsdeterminationof
theirefﬁcacy,inthesettingofacontrolledtrialwhenlogistically
and ethically possible. Plans should include not only the devel-
opment of experimental designs, but also of the logistical steps
requiredtoimplementthenecessaryphysicalandadministrative
infrastructure in each region, including speciﬁcally identiﬁed
personnel. The overall research aims set out by the working
group should be uniﬁed, essentially constituting a multi-center
trial, although the plan for implementation would be tailored
to the speciﬁcs of each country. The integration of African sci-
entists and clinicians into each step of the developing research
program will be vital to its success, along with a long-term plan
to retain them, most likely entailing integration of their activi-
ties into the day-to-day efforts oriented toward more common
endemic diseases.
4.4. Establishing the necessary physical and administrative
infrastructure
Considerableworkwillberequiredtoestablishthenecessary
infrastructure for quality clinical research. Attention must ﬁrst
be paid to developing an avenue for effective communication
with the communities potentially involved. A successful clini-
calresearchprogramcanonlybeestablishedifthecommunities
view themselves as equal partners and trust that the program is
designedtoworkontheirbehalf,evenifthebeneﬁtmightnotbe
immediate. At every step, careful attention must be paid to thor-
oughly communicate the research aims and realistic expected
beneﬁts to local populations likely to be involved, as the conse-
quencesofeventheappearancethatoutsidersareexperimenting
on vulnerable populations would be disastrous. Some degree of
formativesocialscienceresearchmayberequiredtohelpunder-
stand and close the cultural and communication gaps likely to
exist between the researchers and the subjects.
Once solid communication and partnership with the com-
munity are established, attention can be turned to more physical
matters. The transfer of appropriate technology, including the
means for laboratory diagnoses and clinical monitoring, is an
obvious prerequisite. Installation of ﬁxed equipment would be
the most beneﬁcial for the targeted centers in the long-term, but
transient provision of portable point-of-care instruments could
also be envisioned. In some countries, existing research institu-
tionswithtechnicalinfrastructureandexpertiseintheﬁloviruses
could be valuable partners, such as the Centre International de
Recherches M´ edicales de Franceville in Gabon and the Uganda
Viral Research Institute in Uganda. The international organiza-
tionM´ edecinsSansFronti` eres,whichisalreadydeeplyinvolved
inresponsetoﬁlovirusoutbreaks,mayalsoserveasanimportant
partner,especiallywithregardtoprovisionofpatient-care(Jeffs
et al., 2007). Various government and academic institutions
engaged in ﬁlovirus research and with programs in sub-Saharan
Africacouldalsobeimportantpartners.Insomeregionsresearch
infrastructure being established for other diseases, in particular
HIV/AIDs, could also be expanded to encompass work on FHF.
Perhaps even more challenging than the establishment of
the physical infrastructure will be the recruitment, training, and
maintenance of the required personnel. Clinical investigation
teams composed of both local healthcare workers and expatri-
ate technical advisors will need to be established and trained in
advance, ready to move into action with pre-scripted research
protocols, data collection forms (some of which have already
been devised (Colebunders et al., 2007), and culturally appro-
priate methods of informed consent that have already been
approved through an ethical review process in each affected
country.Thismayrequirecreationofinstitutionalreviewboards
in some sub-Saharan countries and research centers. Because of
the sporadic nature of ﬁlovirus outbreaks, protocols may need
to be reviewed, updated, and reapproved at regular intervals.
4.5. Research areas for consideration
Initial research initiatives do not necessarily have to focus on
the testing of experimental products (and probably should not).
Numerous presently approved therapeutic strategies could be
evaluated based on sound scientiﬁc evidence of the pathogene-
sisofFHFandthetreatmentofsepticshock.Althoughcontrolled
trials would be ideal, this may not be ethically possible when
considering the use of many already approved products. Nev-
ertheless, this should not constitute an impediment to their use
and careful monitoring, using historical controls when possi-
ble. Considerable beneﬁt to the patient, as well as increased
knowledge about clinical management of FHF, may be gained
by observational studies.
Themostfundamentalofquestionsandalogicalplacetostart
istoassesstheimpactofaggressivesupportivecare.Althoughno
controlled trials on various types of routine interventions have
been conducted, it is interesting to note that the case-fatality
rate of the only human ﬁlovirus outbreak (excluding isolated
cases) to occur in an area where aggressive supportive care
was routinely possible – Marburg hemorrhagic fever in Ger-
many and Yugoslavia in 1967 – was 22%, compared to 87%
for all other large outbreaks in more remote and undeveloped
areas of sub-Saharan Africa (Anon., 2005; Bausch et al., 2006).
Whether this difference can truly be attributed to the quality of
care or is inﬂuenced by differences in virus strain, route and
dose of infection, underlying prevalence of immunodeﬁciency
and co-morbid illnesses, different intensity of surveillance and
abilitytodetectmildcases,orgeneticsusceptibilityinthepopu-
lations under observation in Europe and Africa is unknown, but
certainly merits study.Author's personal copy
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Speciﬁc areas of clinical study might include assessment of
the efﬁcacy of early goal-directed therapy for hemodynamic
management (Rivers et al., 2001) which has been shown efﬁ-
cacious in studies on septic shock, the optimal composition
of intravenous ﬂuids to be used in resuscitation (Brummel-
Ziedins et al., 2006), the use of blood products and pressor
agents, antibiotic prophylaxis of secondary infection, and the
optimal management of the pregnant patient. The efﬁcacy of
activated protein C, which is already FDA-approved, might be
another area of study, although the ﬁnding of bleeding, some-
times severe, as an adverse effect warrants caution (Bernard et
al., 2001). Trials of experimental compounds, such as antisense
and siRNA, on a compassionate use basis could also be con-
sidered for severe cases not responding to maximal supportive
care. However, given the highly charged atmosphere of most
ﬁlovirus outbreaks, extra care must be made to assure that the
patient and the community understand the experimental nature
of these products in this context. The risk is that communities
may misinterpret and overestimate the potential beneﬁt of com-
passionate use products, and thus be suspicious of accepting
future therapies that may have more potential or even proven
efﬁcacy.
Another possible area for early clinical research is participa-
tion of African countries in Phase I and II testing of promising
therapies and vaccines. Since therapies and vaccines for the
FHFs will be most needed in sub-Saharan Africa, it will be
important that these populations are represented in the safety
testing. These studies would also have the advantage of being
performedinanon-emergentsetting,givingtimetoeducateand
inform the local population about the problem and nature of the
research as well as valuable training in a relatively stress-free
setting for investigators new to the ﬁeld.
The most rigorous and potentially serious clinical research,
Phase III clinical trials, would occur only in the last stages of
this proposed strategy, with personnel and infrastructure now
readied through their experience in the aforementioned stud-
ies. The relatively short duration of most outbreaks of FHF will
require swift action, particularly for vaccine trials. Otherwise,
ongoing outbreak response efforts, which must be implemented
immediately, may limit transmission to a point that assessment
of the vaccine’s protective efﬁcacy would be difﬁcult. Obvi-
ously, the pharmaceutical maker of any new product to be tested
will be a key participant at this stage. This will likely require
dealing with a complex medico-legal environment in order for a
makertoagreetouseoftheirdrug.Considerableconcernscanbe
anticipatedoverbothliabilityandthereputationofthecompany
should any adverse events occur. Although this could be a con-
siderable impediment to pharmaceutical company involvement,
it should be emphasized that, if planned and executed appropri-
ately, the company’s reputation could stand to gain by taking
humanitarian action on behalf of impoverished populations in
sub-Saharan Africa in their time of need.
The research environment established through the above
studies will also provide an important opportunity to explore
the pathogenesis of FHF, comparing data from humans from
thosecollectedinthemanystudiesusinganimalmodels.Impor-
tant questions to be addressed include the relative importance
of humoral versus cellular immunity in recovery, tropism and
timing of infection of various tissues, the precise nature of
the inﬂammatory mediators or inhibitors circulating in FHF
and their mechanism in producing disease or recovery, eluci-
dating the pathophysiologic hemodynamic proﬁles, identifying
prognostic indicators, and exploring genetic determinants of
infection and severe disease.
4.6. Data analysis and statistical power
In addition to the various impediments described above, the
relatively small numbers of cases noted in most ﬁlovirus out-
breaks is often been cited as an insurmountable barrier to Phase
III efﬁcacy trials (Gibbs, 2004). However, the high case-fatality
rates associated with FHF may make up for the small sam-
ple size; a randomized placebo-controlled trial of a treatment
expected to result in a two-fold reduction in case-fatality rate,
say from 80% to 40%, would have 90% power to detect this dif-
ference(2-tailedp<0.05)withtheenrollmentofjust30patients
ineachgroup(totaln=60patients)(Bauschetal.,2007a).Given
the increasing frequency and case counts of ﬁlovirus outbreaks
inrecentyears(Table1),thissamplepopulationcertainlyseems
achievable.Ofcourse,ifmoreaggressivesupportivecarecanbe
routinely implemented and decreases the baseline case-fatality
rate, greater numbers of patients would be required (but a good
problem to have). The multi-center approach described above
should maximize case enrollment. Historical controls may also
be employed, especially for the various species of ebolavirus,
for which case-fatality rates have been relatively consistent
over the years. Lastly, as mentioned above, given how little we
presentlyknowaboutﬁlovirusclinicalsyndromes,evendetailed
systematic observations will certainly considerably expand our
knowledge base even if they do not always allow for rigorous
statistical analysis.
5. Conclusions
Filoviruses continue to plague populations in Central Africa,
with increasing frequency and size of outbreaks in the last
decade. Meanwhile, industrialized countries have conducted
intensive laboratory-based research that is starting to produce
promising therapies and vaccines, bringing the issue of clinical
trials to the forefront. A successful clinical research program
for ﬁloviruses will likely only be established through concerted
advanced planning and the cooperation of a broad array of part-
ners. We propose a multi-center graduated program in which
the original focus would be on establishing the necessary phys-
ical and administrative infrastructure and human resources to
improveandstudytheimpactofaggressivesupportivecare,fol-
lowed by trials of various already-licensed therapies for septic
shock and coagulopathy, and ultimately progressing to Phase II
and III clinical trials of new therapies and vaccines.
This or any approach to patient-oriented research on the
ﬁloviruses will require navigating a complex array of scien-
tiﬁc, logistical, ﬁnancial, and legal challenges. The breadth and
complexity inherent in establishing such a program can only be
brieﬂy touched upon in a single manuscript such as this, andAuthor's personal copy
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our proposed strategy may be only one of various worthwhile
approaches. This communication is intended to spur discussion
and action on this important topic, and will have served its pur-
pose if a clinical research program on FHF can ultimately be
established, regardless of whether the ultimate program con-
forms exactly to the strategy advocated here.
Despite the seeming immensity of the obstacles, sufﬁcient
ﬁeld experience has been garnered in recent years that could,
if the political will is there, be synthesized into a concerted
prospective clinical research program. In fact, there is already
precedent for success, such as the WHO-coordinated Mano
River Union Lassa Fever Network in Sierra Leone, Liberia,
and Guinea, where progress is being made in developing infras-
tructure and international collaboration for research on a VHF
and Category A Select Agent of disease (Lassa fever) in one of
the worlds’ poorest, and until recently war-torn, regions (Khan
et al., 2008). Establishing a clinical research program for the
ﬁlovirusesholdsthepromiseofﬁnallyhavingrealistictherapeu-
ticandpreventiveoptionsforoneofthemostdangerousdiseases
in the world. Furthermore, the knowledge acquired through the
process would likely have signiﬁcant beneﬁt for the treatment
of other VHFs. Lastly, and perhaps of still greater importance,
the research infrastructure created could be applied to the study
and control of a broad array of diseases endemic in sub-Saharan
Africa, including HIV/AIDS and malaria, as well as prepare
African nations for the intrusion of emerging threats such as
avian inﬂuenza.
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